Research Paper Volume 12, Issue 18 pp 18363—18383
A 12-immune cell signature to predict relapse and guide chemotherapy for stage II colorectal cancer
Figure 5. The correlation between immune risk score (namely ISCRC model) and other clinicopathological characteristics in GSE39582 and GSE14333. The distribution of ISCRC, patients’ recurrence status, age, sex, adjuvant chemotherapy, molecular type, tumor location, and immune cells were analyzed in the GSE39582 (A) and GSE14333 (B).